{"id":"daratumumab-and-corticosteroid-treatment","safety":{"commonSideEffects":[{"rate":null,"effect":"Infusion-related reactions"},{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Daratumumab is a monoclonal antibody that targets CD38, a surface antigen highly expressed on multiple myeloma cells, leading to cell death through antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC). Corticosteroids are added to enhance treatment efficacy and manage treatment-related inflammation and immune responses.","oneSentence":"Daratumumab binds to CD38 on multiple myeloma cells to trigger immune-mediated cell death, while corticosteroids provide immunosuppressive and anti-inflammatory support.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:32:07.950Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma (in combination with corticosteroids)"}]},"trialDetails":[{"nctId":"NCT05807048","phase":"PHASE2","title":"Daratumumab in STK11 Mutated NSCLC","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2023-06-01","conditions":"Non-small Cell Lung Cancer With STK11/LKB1 Mutation","enrollment":8},{"nctId":"NCT05434689","phase":"PHASE1, PHASE2","title":"COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2023-01-18","conditions":"Multiple Myeloma","enrollment":80},{"nctId":"NCT07072585","phase":"PHASE2, PHASE3","title":"Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)","status":"NOT_YET_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2026-06-28","conditions":"Stage II T Lymphoblastic Leukemia/Lymphoma, Stage III T Lymphoblastic Leukemia/Lymphoma, Stage IV T Lymphoblastic Leukemia/Lymphoma","enrollment":1708},{"nctId":"NCT05849740","phase":"PHASE4","title":"An Exploratory Study of Cluster of Differentiation 38 (CD38) Monoclonal Antibody Combined Corticosteroid in Acquired Hemophilia A","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2023-05-22","conditions":"Acquired Hemophilia","enrollment":25},{"nctId":"NCT06867991","phase":"PHASE3","title":"Safety and Efficacy of Combined B Cell Depleting theRapy And Daratumumab In Autoimmune Encephalitis","status":"RECRUITING","sponsor":"The First People's Hospital of Changzhou","startDate":"2024-11-08","conditions":"Anti-N-Methyl-D-Aspartate Receptor Encephalitis","enrollment":200},{"nctId":"NCT06663943","phase":"PHASE1, PHASE2","title":"A Randomized Study on Pemphigus Treatment With Humanized CD38 Antibody CM313.","status":"NOT_YET_RECRUITING","sponsor":"Chao Ji","startDate":"2025-10-01","conditions":"Pemphigus Disease, Pemphigus Vulgaris (PV)","enrollment":100},{"nctId":"NCT02951819","phase":"PHASE2","title":"A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2016-11-09","conditions":"Multiple Myeloma","enrollment":101}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Intervention arm"],"phase":"marketed","status":"active","brandName":"Daratumumab and corticosteroid treatment","genericName":"Daratumumab and corticosteroid treatment","companyName":"Institute of Hematology & Blood Diseases Hospital, China","companyId":"institute-of-hematology-blood-diseases-hospital-china","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Daratumumab binds to CD38 on multiple myeloma cells to trigger immune-mediated cell death, while corticosteroids provide immunosuppressive and anti-inflammatory support. Used for Multiple myeloma (in combination with corticosteroids).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}